登录

Qihan Biotech Snared $25.5 Million in A+ Round of Financing

作者: Mailman 2019-09-25 10:52
启函生物
https://www.qihanbio.com/
企业数据由 动脉橙 提供支持
基因编辑技术研发商 | PreB轮 | 运营中
中国-浙江
2023-09-22
融资金额:RMB¥1亿
浙江产业基金
查看

According to PEdaily, Hangzhou Qihan Biotechnology Co., LTD (Qihan Biotech) announced that it had completed the A+ round of financing of 25.5 million dollars, led by CMB International, followed by Legend Star, Xinyi Biological and Bacui Capital, and former investors Sequoia Capital China, Northern Light Venture Capital and other investors in the A round. So far, the total financing amount of Series A comes to 33 million dollars.


Qihan Biotech was founded by George Church, a professor at Harvard University, and Dr. Luhan Yang, a synthetic biologist. Qihan Biotech is committed to producing safe and effective cells tissues and organs for human transplantation, so as to solve the serious shortage of organ transplantation donors in China and the world.


"Qihan Biotech is dedicated to serving patients and bringing hope to the millions of patients and their families waiting for organ donations. This round of financing will be mainly used for pre-clinical research and development of xenotransplantation. With advanced and high-throughput gene-editing technology, Qihan will expand the application of gene-editing in medical and other fields," said Dr. Luhan Yang, the co-founder and CEO of Qihan Biotech.


>>>>

About CMB International


CMB international is a comprehensive and professional financial institution based in Hong Kong. Relying on China Merchants Bank's strength and its social reputation, CMB International provides Hong Kong listing sponsor and underwriting, placement of listed companies and rights, financial advisory, bond issuance services, asset management, direct investment, wealth management, stock sales and trading and other financial services.


>>>>

About Legend Star


Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions, and an entrepreneurs alliance. Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated into the Chinese entrepreneurial ecosystem.


Legend Star is the independent early-stage investment arm of Legend Holdings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.

相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Targene Biotech Raises ¥100M in Series A Financing, Focusing on Early Diagnosis of Tumor

Cyagen Closes on ¥285M Series B Round

MoonBiotech Closes Series B Worth ¥10M

Anngeen Technologies Snags¥100M in Series B Round

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

【首发】怡禾健康完成4000万元A轮融资,第二家诊所已落地

2019-09-25
下一篇

精准医疗咨询公司DeciBio Consulting收购Emmes集团的分子诊断测试和肿瘤学数据库

2019-09-25